Solvay Pharmaceuticals and Novasep Have Signed a Strategic Manufacturing Alliance
Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliance which includes the exclusive synthesis of two active pharmaceutical ingredients for Solvay Pharmaceuticals.
Solvay Pharmaceuticals and Novasep have signed a five-year strategic manufacturing alliancewhich includes the exclusive synthesis of two active pharmaceuticalingredients for Solvay Pharmaceuticals.
Solvay and Novasep have recently set a strategic manufacturingalliance defining Novasep as a preferred partner for the development,the scale-up and the industrial supply of existing or new chemicalentities and/or active pharmaceutical ingredients. Under the terms ofthis 5-years agreement, Novasep currently implement the large scaleproduction of Pinaverium bromide and Betahistine in its Mourenxfacility.
As part of this alliance in the short and mid-term, Novasep andSolvay Pharmaceuticals will start discussion on the possibility toextend this agreement. This outsourcing is in line with SolvayPharmaceuticals strategy of shifting selected manufacturingactivities to high quality, competitively-priced alternatives.
Novasep Synthesis offers exclusive synthesis services utilizingspecialised technologies such as, for instance, chiral technologies,hazardous chemistry, highly potent API to produce elaborate moleculesfor the pharmaceutical industry and combines its exclusive synthesisknow-how and capabilities with its purification technology usingpreparative chromatography to offer a pure and cost-effective API toits customers.
Solvay is an international chemical and pharmaceutical Group withheadquarters in Brussels. It employs some 30,000 people in 50countries. In 2005 its consolidated sales amounted to EUR 8.6 billiongenerated by its three activity sectors: Chemicals, Plastics andPharmaceuticals. SOLVAY (Euronext : SOLB.BE - Bloomberg: SOLB.BB -Reuters: SOLBt.BR) is listed on the Euronext stock exchange inBrussels. Details are available at www.solvay.com
Novasep Synthesis provides R&D and exclusive synthesis, from labto industrial scale, with special expertise in hazardous chemistry,chiral technologies, Highly Potent APIs and Early Stage Services.Novasep Synthesis includes two business units: exclusive synthesisandproprietary products.
Groupe Novasep covers the special needs of the pharmaceutical,food, cosmetics, agrochemicals, and speciality chemicals industries.It binds chemical synthesis and chemical engineering expertise inorder to develop new technologies. The group operates through twodivisions: Novasep Synthesis and Novasep Process focusing on thesynthesis and process of intermediates, advanced intermediates andAPIs.
Best of the Week: Food Analysis, Chemical Migration in Plastic Bottles, STEM Researcher of the Year
December 20th 2024Top articles published this week include the launch of our “From Lab to Table” content series, a Q&A interview about using liquid chromatography–high-resolution mass spectrometry (LC–HRMS) to assess chemical hazards in plastic bottles, and a piece recognizing Brett Paull for being named Tasmanian STEM Researcher of the Year.
Using LC-MS/MS to Measure Testosterone in Dried Blood Spots
December 19th 2024Testosterone measurements are typically performed using serum or plasma, but this presents several logistical challenges, especially for sample collection, storage, and transport. In a recently published article, Yehudah Gruenstein of the University of Miami explored key insights gained from dried blood spot assay validation for testosterone measurement.
Determination of Pharmaceuticals by Capillary HPLC-MS/MS (Dec 2024)
December 19th 2024This application note demonstrates the use of a compact portable capillary liquid chromatograph, the Axcend Focus LC, coupled to an Agilent Ultivo triple quadrupole mass spectrometer for quantitative analysis of pharmaceutical drugs in model aqueous samples.
